Mirvetuximab soravtansine clinical trials
3 indexed studies · 1 currently recruiting
- Active not recruitingPHASE2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
This study looks at a new drug, mirvetuximab soravtansine, with carboplatin for certain types of ovarian, primary peritoneal, or fallopian tube cancer. It's for people whose cancer has come back but responded well to previous platinum-based chemotherapy.
For: High Grade Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube CancerUnited States · Belgium · Canada - RecruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
This study looks at a new drug, Mirvetuximab Soravtansine, for women with advanced ovarian, peritoneal, or fallopian tube cancer that has resisted previous treatments. It aims to see how safe and effective the drug is, especially for cancers with a specific protein.
For: Advanced High-Grade Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube CancersUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum- Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
This study, called MIRASOL, is testing a new drug, Mirvetuximab Soravtansine, against standard chemotherapy for advanced ovarian, peritoneal, or fallopian tube cancers that are resistant to platinum-based treatments and have high folate receptor-alpha.
For: Platinum-Resistant Advanced High-Grade Epithelial Ovarian · Primary Peritoneal · or Fallopian Tube Cancers with High Folate Receptor-Alpha ExpressionFrance